Johnson & Johnson (JNJ)vsScinai Immunotherapeutics Ltd (SCNI)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
SCNI
Scinai Immunotherapeutics Ltd
$0.52
-2.92%
HEALTHCARE · Cap: $767,960
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6680128% more annual revenue ($99.33B vs $1.49M). JNJ leads profitability with a 16.2% profit margin vs -174.8%. SCNI trades at a lower P/E of 0.0x. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SCNI
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for SCNI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 146.0% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -102.5% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : SCNI
The strongest argument for SCNI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 146.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 2.13 — expect wider price swings.
SCNI is growing revenue faster at 146.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 49/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a comprehensive clinical pipeline that aims to deliver transformative therapies to enhance patient outcomes. With a seasoned leadership team and a strong commitment to rigorous research, the company is poised to capitalize on the increasing demand for advanced immunotherapeutics in the global healthcare sector. Strategic partnerships further augment Scinai's growth potential, positioning it as a significant contender within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?